The aim of this parallel screen was to exclude non-MLL-r-selective hits with cytotoxic activity in both cell lines, thereby selecting for compounds more likely to affect the viability of only the MLL-r leukemia cells. The gene discussed is KMT2A; the disease is leukemia.